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Abstract 
It is well documented that caffeine exacerbates the 
hyperthermia associated with acute exposure to 
3,4-methylenedioxymethamphetamine (MDMA) in 
rats. Previous reports have also indicated that 
MDMA-related enhancement of dopamine release 
is exacerbated in the presence of caffeine. In the 
present study we have examined whether the 
effects of MDMA on real-time stimulated dopamine 
release in the absence of uptake inhibition are 
accentuated in the presence of caffeine. Isolated 
striatal slices from adult male Wistar rats were 
treated acutely with MDMA, caffeine, or a 
combination, and their effects on single and 5 pulse 
stimulated dopamine release monitored using the 
technique of fast cyclic voltammetry. Caffeine at 10 
or 100µM had no significant effect on single pulse 
stimulated dopamine release. However 100µM 
caffeine caused a significant peak increase in 5 
pulse stimulated dopamine release. Both 1 and 
30µM MDMA gave rise to a significant increase in 
both single and 5-pulse dopamine release and 
reuptake. A combination of 100 µM caffeine and 1 
or 30µM MDMA did not significantly enhance the 
effects of MDMA on single or 5 pulse dopamine 
release and reuptake when compared to that 
applied alone.  Utilizing single action potential 
dependent dopamine release, these results do not 
demonstrate a caffeine-enhanced MDMA-induced 
dopamine release. 
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1. INTRODUCTION 
3,4-methylenedioxymethampetamine (MDMA) or 
ecstasy is a popular synthetic drug of abuse, which 
has many neuropharmacological activities including 
those on the serotonergic and dopaminergic 
systems in the CNS (Green et al., 2003). MDMA 
inhibits the reuptake of 5-HT, facilitates serotonin 
release, and causes the release of dopamine and 
noradrenaline (Lyles and Cadet, 2003). Therefore 
MDMA increases the amount of extracellular 
serotonin and dopamine, a mechanism thought to 
involve at least partially, the reversal of the 
membrane serotonin and dopamine transporters 
(SERT and DAT respectively; Green et al., 1995; 
Crespi et al., 1997; Iravani et al., 2000). Numerous 
investigators have confirmed the dopamine-
releasing actions of MDMA using tritiated dopamine 
(Johnson et al., 1986, Fitzgerald & Reid, 1990), in 
vivo microdialysis  (Gudelsky et al., 1994) and 
voltammetry (John & Jones, 2007; Iravani et al., 
2000). Thus the acute effects of MDMA on brain 
monoamines may result from the ability of the drug 
to modulate 5-HT and dopamine release and 
reuptake (Johnson et al., 1986). Also, long-term 
exposure to MDMA may cause a selective 
decrease in brain concentrations of 5-HT and 
dopamine, possibly due to loss of 5-HT and 
dopamine nerve terminals in various brain regions 
(Green et al., 1995).  
 
Caffeine is probably the most highly consumed 
psychoactive drug in the world and also has acute 
effects on dopamine release (Reith et al., 1987). It 
is a non-selective adenosine receptor antagonist 
that targets mainly adenosine A1 and A2a receptors 
in the brain (Okada et al., 1997; Solinas et al., 
2002; Quarta et al., 2004; Ferre et al., 2008a,b). We 
have previously shown that adenosine A1 receptor 
mediated inhibition of dopamine release from rat 
striatal slices is modulated by D1 dopamine 
receptors (O’Neill et al., 2007). Several studies 
have shown that adenosine and dopamine 
receptors do not function independently of each 
other, but rather interact with each other at a 
number of levels (Ferre et al., 2008a,b; Mango et 
al., 2014). Antagonistic interactions have been 
demonstrated between A1 and D1 and A2a and D2 
dopamine receptors (O’Neill et al., 2007). However 
the extent to which these interactions between 
adenosine and dopamine receptors affect the 
regulation of dopamine release is still unknown. 
 
Previous studies have indicated a number of 
neurotoxic effects of the combination of MDMA and 
caffeine in the brain (Derlet et al., 1992; Ikeda et al., 
2011 and reviewed in Vanattou-Saïfoudine et al., 
(2010a)). In rats, caffeine acts synergistically with 
MDMA in producing hyperthermia (Vanattou-
Saifoudine et al., 2010a. 2010b; McNamara et al., 
2006; O'Loinsigh et al., 2001), changes in 
locomotion (Antoniou et al., 2005) and dopamine 
release (Vanattou-Saifoudine et al., 2011, Sinchai 
et al., 2011). Taken together, all of these reports 
support the view that caffeine facilitates acute and 
indeed long-term toxicity associated with MDMA.  
 
Most of these studies to date have used long 
durations of continuous stimulation, electrical and 
chemical, to evoke dopamine release and often in 
the presence of dopamine uptake inhibitors in order 
to be able to measure sufficient dopamine levels. 
For example in most microdialysis studies electrical 
and chemical stimuli protocols can last for many 
 2 
seconds and thus activate many receptor subtypes 
including autoreceptors. In this study we have used 
an alternative study protocol to previous work 
utilizing discrete single short-term stimuli evoking 
single and multiple action potentials pre-
synaptically. The temporal resolution of fast cyclic 
voltammetry, applied at up to 100 scans per second 
(‘real-time’ measurement), can monitor the release 
of dopamine at the sub-second level (O’Connor & 
Lowry, 2012). In this study we compared a single 
(0.1ms) stimulus to a 5-pulse (at 10Hz, lasting 
400ms) stimulus and monitored dopamine release 
every 250 ms. We show modulatory effects of both 
caffeine and MDMA on single and 5 pulse 
dopamine release. However under minimal pulse 
stimulation and in the absence of dopamine 
reuptake inhibitors, we demonstrate that acute 
MDMA-induced dopamine release is not enhanced 
in the presence of caffeine.  
 
 
2. MATERIALS AND METHODS 
2.1. Experimental Preparation 
2.1.1. Brain slices 
Male Wistar rats (178-283g), housed 4 to a cage, 
were purchased by Maynooth University, fortnightly 
from Harlan, UK and kept in the BioResources Unit 
in Maynooth. All experiments were carried out in 
accordance with the guidlines of the animal ethics 
committe of NUIM and the European Communities 
Council Directive of 24 November 1986 
(86/609/EEC). Rats were killed by decapitation. The 
brain was quickly removed into ice-cold artifical 
cerebrospinal fluid (aCSF). Blocks of tissue 
containing the caudate putamen and nucleus 
accumbens were prepared. 350 µm thick slices 
were sectioned using a Campden vibrotome. Brain 
slices were then transferred to a holding chamber 
containing aCSF (see below) at room temperature 
(20-21oC) to equilibrate for 1 h. A single slice was 
then transferred to a recording chamber and 
superfused with oxygenated aCSF at 4 ml.min-1 at 
30-31°C for 40 min before electrical stimulation.  
2.1.2. Measurement of endogenous dopamine 
release 
Following 40 min equilibration, a bipolar tungsten-
stimulating electrode with a tip separation of 200 
µm (A-M Systems, Inc.) was placed in the 
dorsolateral caudate putamen (see Figure 1). A 
carbon fiber electrode (7 µm diameter carbon fiber; 
50-100 µm exposed length) was placed 100-200 
µm from the stimulating microelectrode. Fast cyclic 
voltammetry (FCV; Millar Voltammeter; Dr. Julian 
Millar, Queen Mary & Westfield College, University 
of London, UK) at the carbon fiber electrode was 
used to detect changes in extracellular 
concentrations of dopamine following electrical 
stimulation of the brain slice (Palij et al., 1990). A 
basic triphasic voltage waveform (ranging from -1.0 
to +1.0 V; 20 ms duration), generated using a Millar 
voltammeter (Millar & Barnett, 1988) was applied to 
the carbon fiber electrode at 4 Hz (every 250 ms; 
Figure 1A). This waveform was modified from our 
‘extended’ waveform (-1.0 to +1.4 V; see Stamford, 
1990) where MDMA is electroactive, producing 
oxidation currents that interfere with the oxidative 
currents for dopamine. Using the basic waveform 
MDMA is electrochemically inert whilst the 
sensitivity of FCV to dopamine is maintained (see 
Irivani et al., 2000). A sample and hold device built 
into the Millar voltammetry monitored dopamine 
release at +610 mV during each scan (Figure 1B, 
C). Stimulated dopamine release (using Neurolog 
modules) was evoked using a square-wave pulse of 
10 V amplitude and 100 µs duration delivered once 
every 2 min (O’Connor & Lowry, 2012). 
 
Figure 1  Waveforms used in FCV 
A. A triphasic voltage ramp is passed down the carbon 
fiber electrode twice per second. The ramp sweeps from 0 
V (relative to silver/silver chloride reference electrode) to -
1.0 V to +1.0 V to -1.0 V and back to 0 V. This sweep lasts 
20 ms. B. The resultant current measured by the carbon 
fiber electrode in called the charging current. 
Superimposed on the charging current is the current 
obtained when the electrode is placed in aCSF solution 
containing 1 µM dopamine. C. If the charging current in B 
in the absence of dopamine is subtracted from the current 
in the presence of dopamine a trace typical of C is the 
result (subtraction voltammogram). This is known as the 
faradaic current and is the result of the oxidation and 
reduction of dopamine on the surface of the carbon fiber 
electrode. Dopamine oxidizes at approximately +610 mV 
and is reduced at -200 mV. 
D. The trace illustrated in D is the result of a sample and 
hold device measuring at +612 mV during the electrical 
stimulation of the striatum. The arrow indicates the time of 
stimulation of striatum (0.1 ms pulse width; 10 V). Post 
calibration of the carbon fiber electrode indicated that 
approximately 0.1µM dopamine is evoked by a single 
electrical stimulation in the dorsolateral striatum, peak rise 
time 0.5-1 s and half decay time approximately 0.75-1.25 
s.  E. Schematic diagram illustrating the placement of the 
carbon fibre microelectrode (recording electrode) and the 
bipolar stimulating electrodes in the dorsolateral striatum. 
 
A sample and hold output before during and after a 
stimulus is shown in Figure 1D. Dopamine release 
under these conditions is tetrodotoxin-sensitive and 
Ca2+-dependent (Palij et al., 1990). Sample and 
hold data were recorded onto a computer via a 2 
channel MacLab. Electrodes were calibrated with 
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increasing concentrations of freshly prepared 
dopamine in the range 0.05 µM to 1 µM, 
concentrations in the range of the endogenous 
dopamine released in the slices (see O’Neill & 
O’Connor, 2008).  
 
2.2. Experimental Protocols 
Single pulse dopamine was stimulated every 2 min 
during the course of the experiment. Every 30 min a 
multiple pulse stimulation protocol was carried out 
(5 pulses at 10 Hz). Dopamine D2 antagonists have 
previously been shown to increase this signal 
(Limberger et al., 1991) but not by others (Trout and 
Kruk, 1992). Two concentrations of caffeine and 
MDMA were applied to the slices; for caffeine, 30 
min baseline control, 30 min 10 µM, and 30 min 100 
µM; for MDMA, 30 min baseline, 30 min 1 µM and 
30 min 30 µM compound. For the combined 
protocol 1 and 10 µM MDMA were each superfused 
for 30 min in the presence of 100 µM caffeine. 
2.3. Drugs and Materials 
Artificial cerebrospinal fluid (aCSF) was prepared 
every day according to the following composition in 
mM: NaCl, 120; KCl, 2.5; MgSO4, 2; CaCl2, 2; 
NaH2PO4, 1.25 and D-glucose, 10 mM in H2O. 
aCSF was bubbled with 95% O2/5% CO2. Caffeine 
(Sigma) and MDMA custom synthesized by G. 
Boland, Royal College of Surgeons in Ireland using 
the methods of Braun et al., (1980)) were dissolved 
in de-ionised water to a concentration of 10-2M and 
stored at -20oC in 100 µL volume containers. 
Compounds were used within 5 days of 
preparation.  
2.4. Data analysis 
All sample and hold data were analyzed and peak 
dopamine release measured at 4Hz. These values 
were exported into Excel sheets. Single pulse 
evoked dopamine overflow was measured as the 
peak release in response to electrical stimulation. 
Half decay time (t1/2) of dopamine release was 
measured from peak release to 50% half decay. 
Stimulated dopamine release was measured over 6 
min (3 stimulations) prior to the first test drug 
application and the average of these 3 values were 
taken as 100%. All values prior and subsequent to 
these were represented as % control. Data are 
presented as means±standard error of the mean 
(s.e.m.) of n independent experiments (brain slices 
from different animals). One-way ANOVA with post 
Bonferroni test was carried out in Figures 3 and 4 
for the individual effects of caffeine and MDMA on 
single and 5 pulse stimulated dopamine release. In 
Figure 3B and D the Students paired t-test was 
used to calculate the effects of caffeine or MDMA 
on half decay times. In Figure 4 in order to analyze 
the interaction of caffeine and MDMA on dopamine 
release we used a 2-way ANOVA with post 
Bonferroni test. Calculations for single pulse 
dopamine release were based on the values from 
the last 10 minutes in each group. P<0.05 was 
considered significant. 
 
 
 
 
 
 
3. RESULTS 
3.1. Control experiments 
Single pulse dopamine release was evoked 
every 2 min (10V; 0.1ms duration) and was 
stable for more than 3 hrs (Figure 2A). 
Typically evoked single pulse release ranged 
from 0.05 to 0.12 µM dopamine when 
measured against the calibrated electrodes. 
Control rise times and half decay times ranged 
from 0.5 to 0.75 and 0.5 to 1 s respectively. 5 
pulses at 10 Hz (multiple pulse stimulation; 
asterisks), was evoked every 30 min and was 
also stable for more than 3 hrs (Figure 2A and 
B).  
 
Figure 2. Control experiments carried out using fast 
cyclic voltammetry in slices of the rat striatum.  
A. Typical sample and hold data trace showing single 
pulse stimulated (10V, 0.1ms) dopamine release every 2 
min over a 20 min period (10 stimulations). The trace has 
been subjected to triangular (Bartlett) window (width 15) 
filtering (Chart 6.1). The arrows indicate the points of 
stimulation. The larger arrow towards the end of the trace 
indicates that a 5-pulse stimulation (at 10 Hz) has been 
carried out. This was typically 1.4 to 1.6 times bigger than 
single pulse stimulation. Insets show on an extended time-
base an example of a single pulse stimulated release of 
dopamine (left) and that of a 5 pulse stimulated response 
(right). B. Averaged time course data over a 90-min 
period. Asterisks indicate the occurrence of the 5-pulse 
protocol. Peak dopamine release was measured from the 
base to maximum peak post stimulation using Chart Zoom 
and exported to Excel™. The average of the last 3 values 
prior to compound application was taken as 100% and all 
values subsequent to these were represented as % 
control (normalized).  Data are presented as 
means±standard error of the mean (s.e.m.) of 5 
independent experiments (different brain slices). 
 
3.2. Effects of caffeine or MDMA on single 
and 5-pulse evoked dopamine release 
Caffeine at 10 µM had no significant effect on 
peak single or 5 pulse stimulated dopamine 
release. However 100 µM caffeine caused a 
significant increase in peak stimulated 5 pulse 
dopamine release (Figure 3A; P<0.05, n=5). 
Caffeine also caused a significant increase in 
 4 
the half decay time for both 1 pulse and 5 pulse 
stimulated dopamine release (Figure 3B; 
P<0.05 for both). Both 1 and 30 µM MDMA had 
significant effects on both peak single and 5-
pulse dopamine release (Figure 3C; P<0.001 
and P<0.05 respectively; n=5 for both). MDMA 
at both concentrations also significantly 
increased the half decay time (t1/2) for single 
and 5 pulse dopamine release (Figure 3D and 
D; P<0.05, n=5 for both single and 5 pulse 
stimulated dopamine release).  
 
 
Figure 3. Effects of Caffeine or MDMA on stimulated 
dopamine release.  
A. Averaged time course data showing the effect of 10 µM 
and 100 µM caffeine on peak single and 5-pulse 
stimulated dopamine release. The upper four points 
represent the 5-pulse protocol every 30 min. Caffeine did 
not have any effect on single pulse release at both of the 
concentrations. However peak dopamine release evoked 
by 5 pulses at 10Hz was significantly enhanced by 100 
µM caffeine (*P<0.01, compared to control).  B. Averaged 
data for the effects of 10 µM and 100 µM caffeine on the 
half decay time (t1/2) of single pulse (white bars) or 5 pulse 
(black bars) stimulated dopamine release. 100 µM 
caffeine significantly increased the half-time for reuptake 
for both 1 and 5 pulse stimulated release (0.95±0.1 to 
1.4±0.13 s and 1.1±0.13 to 1.5±0.24, respectively, 
*P<0.05, n=5).  C. Averaged time course data showing the 
effect of 1 µM and 30 µM MDMA on peak single and 5-
pulse stimulated dopamine release. The upper four points 
represent the 5-pulse protocol every 30 min. MDMA gave 
rise to a significant increase in peak single pulse and 5 
pulse evoked dopamine release at both concentrations 
(single pulse, +P<0.01; 5-pulse, *P<0.05, compared to 
control). D. Averaged data for the effects of 1 µM and 30 
µM MDMA on the half decay time (t1/2) of single pulse 
(grey hatch bars) or 5-pulse (black hatch bars) stimulated 
dopamine release. 30 µM MDMA significantly increased 
the half-time for reuptake for both 1 and 5-pulse 
stimulated release (0.9±0.1 to 1.4±0.21 s and 1.1±0.15 to 
1.5±0.21, respectively, *P<0.05, n=5).  
 
3.3. Effects of a combination of caffeine and 
MDMA on dopamine release 
Perfusion of 100 µM caffeine 30 min prior to the 
application of 1 and 30 µM MDMA did not 
significantly change the effects of MDMA on single 
pulse stimulated dopamine release when compared 
to MDMA applied alone (Figure 4A and C; F(1, 
10)=2.25, P=0.127, for MDMA alone versus 
caffeine+MDMA). Similar results were observed for 
5 pulse stimulated dopamine release when caffeine 
and MDMA were co-applied (Figure 4D; F(1, 
10)=1.78, P=0.19). 
 
 
Figure 4. Effects of a combination of Caffeine and 
MDMA on stimulated dopamine release.  
A. Averaged time course data showing the effect of 1 µM 
and 30 µM MDMA on single and 5-pulse stimulated 
dopamine release in the presence of 100 µM caffeine. B. 
Summary bar graph showing the effects of MDMA alone 
and in combination with caffeine (100 µM) on peak single 
pulse stimulated dopamine release. The data in Figure 3C 
and that above (A) have been compared here. Using a 2-
way ANOVA it was found that there was no significant 
interaction between caffeine and the effects of MDMA. C. 
Summary bar graph showing the effects of MDMA alone 
and in combination with caffeine (100 µM) on 5-pulse 
stimulated dopamine release. The data in Figure 3C and 
that above (A) have been compared here for 5-pulse data. 
Using a 2-way ANOVA it was found that there was no 
significant interaction between caffeine and the effects of 
MDMA. 
 
4. DISCUSSION 
In this study we have investigated whether 
application of caffeine (and activation of adenosine 
receptors) might interact synergistically with the 
effects of MDMA to modulate single or 5 pulse 
evoked release of dopamine from rat striatal slices. 
Whilst there is good evidence for an MDMA-related 
enhancement of dopamine release coupled to a 
caffeine-mediated antagonism of adenosine 
receptors using different methodologies to that used 
here, we show that prior addition of caffeine does 
not give rise to a greater effect of MDMA on 
dopamine release. In contrast to prior publications 
the present data were derived from experiments 
where dopamine D2 autoreceptors are not activated 
by endogenous dopamine (Bull & Sheehan, 1991). 
Limberger et al., (1991) has previously shown that 
dopamine D2 auoreceptors are only activated by 
stimulated endogenous dopamine following 
electrical stimulation lasting a minimum of 200 ms. 
As has previously been shown using the 
methodology of FCV (John & Jones, 2007; Iravani 
et al., 2000) and other techniques (Gudelsky et al., 
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1994; Fitzgerald and Reid, 1990; Johnson et al., 
1986), we have also shown that MDMA applied 
alone enhances the amount of dopamine released 
and decreased the rate of its reuptake in striatal 
slices (increased reuptake time). We have also 
demonstrated, albeit at high concentrations, a 
stimulatory effect of caffeine on dopamine release 
as has also previously been demonstrated (Okada 
et al., 1997). However, the combination of caffeine 
and MDMA did not enhance the effect of either drug 
applied alone using our specific stimulation 
protocols. 
In the rat striatum dopaminergic neurons are known 
to exhibit patterns of ‘regular’ (tonic) and high 
frequency ‘burst’ firing (Overton & Clark, 1997) 
whereby action potentials can be generated singly 
or in bursts of up to ten to twenty. Electrical 
stimulation protocols can be designed to mimic 
either mode and examine their effects on dopamine 
release. In most studies, which in fact use burst 
firing or long durations of stimulation, there is a 
transient increase in extracellular dopamine while in 
other studies tonic firing may cause a new steady-
state level of dopamine release (Venton et al., 
2003). Previous work by Phillips & Stamford, (2000) 
using a similar technique to that used in these 
experiments and similar brain regions, namely 
striatal slices, suggest that the dorsolateral caudate 
putamen comprises ‘regular’ neuronal firing, since it 
has more subtypes of presynaptic calcium channels 
and the medial axis of the dorsolateral caudate may 
respond more efficiently to ‘burst’ firing. This is 
consistent with the observed function in these 
regions, where significantly greater dopamine efflux 
is measured in the medial axis than in the 
dorsolateral caudate putamen for high frequency 
train stimulations. In this study we have used 
discrete single-pulse stimulation in the dorsolateral 
region of the striatum, which is likely to be similar to 
regular neuronal firing. The use of high frequency 
pulse stimulations would approximate bursts of 
electrical activity in these cells but would in the 
process activate D2 autoreceptors. Whether this 
alone might account for the differences in the effect 
of caffeine/MDMA on dopamine release remains to 
be determined. We have also shown that the 5 
single pulses delivered at 10Hz gave rise to 
dopamine release that was not further affected by 
application of both compounds. Even thought this 
represents a train stimulation lasting 400ms and 
presumably some D2 autoreceptor activation, we do 
not believe it is a strong stimulation and that the 
frequency of delivery is low (see Trout & Kruk, 
1992). 
It has been suggested that caffeine may facilitate 
MDMA toxicity predominately by the activation of 
dopamine D1 receptors (Vanattou-Saïfoudine et al., 
2012a,b; Mohamed et al., 2011; Vanattou-
Saïfoudine et al., 2010b). Also mice that have been 
administered caffeine (10 mg/kg) prior to MDMA (5 
mg/kg) show a potentiated MDMA-induced 
locomotor activity (Camarasa et al., 2006). 
Therefore overall it has been hypothesized that 
caffeine blocks adenosine A2 receptors, potentiating 
dopamine release and increasing MDMA-related 
hyper locomotion (Camarasa et al., 2006). 
Moreover, caffeine may act via inhibition of 
adenosine A1 receptors to increase MDMA-induced 
striatal dopamine release (Vanattou-Saïfoudine et 
al., 2011). Also we have previously shown using 
similar techniques to those carried out here that 
dopamine D1 receptors play a role in the inhibition 
of dopamine by A1 receptor activation (O’Neill et al., 
2007). 
Our studies involved the administration of MDMA 
acutely onto rat brain slices. It is accepted that 
acute behavioral and body temperature changes in 
rat and humans result from rapid MDMA-induced 
monoamine release, whereas long-term 
neurotoxicity is primarily caused by metabolites of 
the drug (Albers & Sonsalla, 1995; Green et al., 
2012). In these preliminary experiments we did not 
investigate any of these metabolites and their 
interaction with caffeine. It also seems that plasma 
MDMA concentrations and functional outcome are 
similar in rats and humans at low dose 
administration but not at high concentrations (Green 
et al., 2012). Therefore acute application of MDMA 
may not be comparable to in vivo human studies 
where metabolites are formed (Baumann et al., 
2009). Finally the rate of metabolism of MDMA and 
its major metabolites is slower in humans than in 
rats and this may have to be considered when 
utilizing rat models. 
In conclusion whilst there is unequivocal evidence 
that caffeine acts synergistically with MDMA on 
dopamine release, this effect is not seen when 
dopamine is evoked by single and 5 pulse 
stimulation. 
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